Open AccessSitagliptin-induced hemolysis
Author(s) -
Ragini Bekur,
M R Nagaraja,
KN Shivashankara,
Weena Stanley
Publication year - 2010
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.70405
Subject(s) - sitagliptin , medicine , hypoglycemia , dipeptidyl peptidase 4 inhibitor , dipeptidyl peptidase 4 , adverse effect , drug , pharmacology , diabetes mellitus , type 2 diabetes mellitus , hemolysis , type 2 diabetes , endocrinology
Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent. The advantages are the absence of hypoglycemia when used as monotherapy and they cause less gain weight. We report a case of sitagliptin-induced hemolysis, a rare side effect, not reported in the literature. As sitagliptin is widely used in type 2 diabetes mellitus physicians should be aware of the possibility of this rare but potentially serious adverse drug reaction.